SUNPHARMA
524715Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma participates in White House Signing Ceremony highlighting U.S. Medicines Pricing and Access Commitments
Sun Pharmaceutical Industries Ltd is a leading global specialty generic pharmaceutical company headquartered in Mumbai, India. Established in 1983, Sun Pharma manufactures and markets a wide array of pharmaceutical formulations, serving more than 100 countries with a focus on the US, India, and emerging markets. The company's product portfolio spans branded generics, complex generics, specialty products, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products across various therapeutic areas including cardiology, psychiatry, neurology, gastroenterology, and oncology.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma participates in White House Signing Ceremony highlighting U.S. Medicines Pricing and Access Commitments
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisements about Postal Ballot/E-voting
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot/E-voting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Update On Lipitor Antitrust Litigation
Update on Lipitor Antitrust Litigation
Receipt Of No-Objection Letters From The Stock Exchanges For Reclassification Of Promoter Group
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q1FY27 Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Credit Rating
Update on Credit Rating
Sun Pharmaceutical Industries Ltd
About
Sun Pharmaceutical Industries Ltd is a leading global specialty generic pharmaceutical company headquartered in Mumbai, India. Established in 1983, Sun Pharma manufactures and markets a wide array of pharmaceutical formulations, serving more than 100 countries with a focus on the US, India, and emerging markets. The company's product portfolio spans branded generics, complex generics, specialty products, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products across various therapeutic areas including cardiology, psychiatry, neurology, gastroenterology, and oncology.
Sun Pharma is recognized for its substantial R&D capabilities, with multiple state-of-the-art research centers and a strategic emphasis on differentiated products. Through a mix of organic growth and strategic acquisitions, Sun Pharma has evolved into India’s largest pharmaceutical company by revenue and maintains a strong presence in global regulated markets.
Business Model & Strategy
Sun Pharma earns its revenue primarily through the development, manufacture, and global distribution of pharmaceutical formulations and APIs. The business is diversified, with significant contributions from the US generics market, specialty portfolios (including dermatology and ophthalmology), and branded generics in India and other emerging markets. Strategic investments in R&D and regulatory compliance underpin its expansion into complex generics and specialty medicines, targeting niche therapeutic areas with minimal competition.
The company pursues growth by expanding its specialty pipeline, forging partnerships for in-licensing innovative molecules, and leveraging its operational efficiencies. Sun Pharma continues to focus on new product launches in key global markets, integration of recent acquisitions, and strengthening its US and emerging market reach to drive sustainable growth.
Management Overview
10 MembersMr.Dilip Shantilal Shanghvi
Executive Director-Chairperson related to Promoter-MDMr.Pawan Kumar Goenka
Non-Executive - Independent DirectorMr.Gautam Bhailal Doshi
Non-Executive - Independent DirectorMs.Rama Bijapurkar
Non-Executive - Independent DirectorMr.Rolf Hoffmann
Non-Executive - Independent DirectorMr.Sudhir Vrundavandas Valia
Non-Executive - Non Independent DirectorMr.Aalok Dilip Shanghvi
Executive DirectorMs.Vidhi Dilip Shanghvi
Executive DirectorMs.Jayashree Satagopan
Chief Financial OfficerMr.Anoop Deshpande
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Listed in Forbes Global 2000 (2024)
- ET Best Brands in Pharmaceuticals (2023)
- Ranked among India's Top 10 Most Trusted Pharmaceutical Brands (Brand Trust Report 2023)
- Included in S&P Global Sustainability Yearbook (2024)
- Received Pharmexcil Awards for pharma exports (2023)
Market Information
Company Timeline
41+ Years of Excellence | 9 Major Milestones
Sun Pharmaceutical Industries Ltd founded in Vapi, Gujarat
Initial Public Offering (IPO) on Indian stock exchanges
Established first research center in Baroda
Acquisition of Taro Pharmaceutical Industries
Acquisition of Ranbaxy Laboratories, making Sun Pharma India’s largest and world's 5th largest specialty generic pharma company
Foray into specialty medicines through the launch of Ilumya (tildrakizumab) for dermatology in the US
Announced new R&D investments focused on specialty and complex generics
Received USFDA approvals for multiple complex generics; expanded specialty product launches
Ranked in S&P Global Sustainability Yearbook; expanded dermatology and ophthalmology portfolio in the US
The Next Evolution
Contact Information
Registered Office
SPARC, Tandalja
Tel: 0265-5515500 / 5515600,
Fax: 0265-2354897,
Email: secretarial@sunpharma.com
Website: sunpharma.com
Corporate Actions
20| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹5 per share | 07 Jul 2026 Tuesday | 07 Jul 2026 Tuesday | - | - |
Interim Dividend ₹11 per share | 05 Feb 2026 Thursday | 05 Feb 2026 Thursday | - | - |
Final Dividend ₹5.50 per share | 07 Jul 2025 Monday | 07 Jul 2025 Monday | - | - |
Interim Dividend ₹10.50 per share | 06 Feb 2025 Thursday | 06 Feb 2025 Thursday | - | - |
Final Dividend ₹5 per share | 12 Jul 2024 Friday | 12 Jul 2024 Friday | - | - |
Interim Dividend ₹8.50 per share | 09 Feb 2024 Friday | 09 Feb 2024 Friday | - | - |
Final Dividend ₹4 per share | 28 Jul 2023 Friday | 28 Jul 2023 Friday | - | - |
Interim Dividend ₹7.50 per share | 08 Feb 2023 Wednesday | 08 Feb 2023 Wednesday | - | - |
Final Dividend ₹3 per share | 19 Aug 2022 Friday | 22 Aug 2022 Monday | - | - |
Interim Dividend ₹7 per share | 09 Feb 2022 Wednesday | 10 Feb 2022 Thursday | - | - |
Final Dividend ₹2 per share | 23 Aug 2021 Monday | - | 25 Aug 2021 Wednesday | 31 Aug 2021 Tuesday |
Interim Dividend ₹5.50 per share | 09 Feb 2021 Tuesday | 10 Feb 2021 Wednesday | - | - |
Final Dividend ₹1 per share | 19 Aug 2020 Wednesday | - | 21 Aug 2020 Friday | 27 Aug 2020 Thursday |
Interim Dividend ₹3 per share | 17 Feb 2020 Monday | 18 Feb 2020 Tuesday | - | - |
Dividend ₹2.75 per share | 20 Aug 2019 Tuesday | - | 22 Aug 2019 Thursday | 28 Aug 2019 Wednesday |
Dividend ₹2 per share | 17 Sep 2018 Monday | - | 19 Sep 2018 Wednesday | 26 Sep 2018 Wednesday |
Dividend ₹3.50 per share | 18 Sep 2017 Monday | - | 20 Sep 2017 Wednesday | 26 Sep 2017 Tuesday |
Dividend ₹1 per share | 08 Sep 2016 Thursday | - | 10 Sep 2016 Saturday | 17 Sep 2016 Saturday |
Buy Back of Shares | 14 Jul 2016 Thursday | 15 Jul 2016 Friday | - | - |
Dividend ₹3 per share | 21 Oct 2015 Wednesday | - | 24 Oct 2015 Saturday | 31 Oct 2015 Saturday |
₹4,62,352 Cr.
₹1,930
₹2,047 / 1,548
41.09
₹349.6
5.51
₹46.9
₹1.00
0.83 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 30,091 | 33,473 | 34,334 | 39,576 | 44,520 | 49,851 | 54,543 | 60,434 | 47,193 |
| Expenses | - | - | - | 25,067 | 28,203 | 27,228 | 30,528 | 34,940 | 38,269 | 40,114 | 44,007 | 34,622 |
| Profit | - | - | - | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 | 8,992 |
| Tax | - | - | - | 601 | 823 | 515 | 1,076 | 848 | 1,439 | 2,772 | 3,554 | 2,842 |
| EPS | - | - | - | 11 | 16 | 12 | 14 | 35 | 40 | 46 | 48 | 12.1 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 64,694 | 68,252 | 67,667 | 69,800 | 80,744 | 85,463 | 92,101 | 1,08,785 | - |
| Equity And Liabilities | - | - | - | 64,694 | 68,252 | 67,667 | 69,800 | 80,744 | 85,463 | 92,101 | 1,08,785 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 20 Apr '19 | Mar 2020 30 Apr '20 | Mar 2021 20 Apr '21 | Mar 2022 19 Apr '22 | Mar 2023 21 Apr '23 | Mar 2024 18 Apr '24 | Mar 2025 17 Apr '25 | Mar 2026 17 Jun '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 54.38% | 54.69% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | - |
| Non Institutions | - | - | - | 12.76% | 12.94% | 12.23% | 11.06% | 9.39% | 8.97% | 8.87% | 8.48% | - |
| FII | - | - | - | - | - | - | - | 16.89% | 17.72% | 17.96% | 15.93% | - |
| DII | - | - | - | - | - | - | - | 19.24% | 18.83% | 18.70% | 21.11% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd is a leading global specialty generic pharmaceutical company headquartered in Mumbai, India. Established in 1983, Sun Pharma manufactures and markets a wide array of pharmaceutical formulations, serving more than 100 countries with a focus on the US, India, and emerging markets. The company's product portfolio spans branded generics, complex generics, specialty products, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products across various therapeutic areas including cardiology, psychiatry, neurology, gastroenterology, and oncology.
Sun Pharma is recognized for its substantial R&D capabilities, with multiple state-of-the-art research centers and a strategic emphasis on differentiated products. Through a mix of organic growth and strategic acquisitions, Sun Pharma has evolved into India’s largest pharmaceutical company by revenue and maintains a strong presence in global regulated markets.
Sun Pharma earns its revenue primarily through the development, manufacture, and global distribution of pharmaceutical formulations and APIs. The business is diversified, with significant contributions from the US generics market, specialty portfolios (including dermatology and ophthalmology), and branded generics in India and other emerging markets. Strategic investments in R&D and regulatory compliance underpin its expansion into complex generics and specialty medicines, targeting niche therapeutic areas with minimal competition.
The company pursues growth by expanding its specialty pipeline, forging partnerships for in-licensing innovative molecules, and leveraging its operational efficiencies. Sun Pharma continues to focus on new product launches in key global markets, integration of recent acquisitions, and strengthening its US and emerging market reach to drive sustainable growth.
Listed in Forbes Global 2000 (2024)
ET Best Brands in Pharmaceuticals (2023)
Ranked among India's Top 10 Most Trusted Pharmaceutical Brands (Brand Trust Report 2023)
Included in S&P Global Sustainability Yearbook (2024)
Received Pharmexcil Awards for pharma exports (2023)
Sun Pharmaceutical Industries Ltd founded in Vapi, Gujarat
Initial Public Offering (IPO) on Indian stock exchanges
Established first research center in Baroda
Acquisition of Taro Pharmaceutical Industries
Acquisition of Ranbaxy Laboratories, making Sun Pharma India’s largest and world's 5th largest specialty generic pharma company
Foray into specialty medicines through the launch of Ilumya (tildrakizumab) for dermatology in the US
Announced new R&D investments focused on specialty and complex generics
Received USFDA approvals for multiple complex generics; expanded specialty product launches
Ranked in S&P Global Sustainability Yearbook; expanded dermatology and ophthalmology portfolio in the US
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon